Key Takeaways Bristol Myers and BioNTech's pumitamig plus chemo showed a 76.3% response rate in ES-SCLC.The phase II trial data supported dose selection for the pivotal ROSETTA LUNG-01 study.Pumitamig received FDA Orphan Drug status for small cell lung cancer treatment in 2025.Bristol Myers ((BMY) and partner BioNTech ((BNTX) recently presented interim data from a global randomized mid-stage study evaluating pumitamig plus chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). Pumit ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best inexpensive stocks to buy according to hedge funds. On September 8, BioNTech (NASDAQ:BNTX) and Bristol Myers Squibb presented positive interim data from a global randomized Phase 2 trial of their investigational bispecific antibody, pumitamig (BNT327/BMS986545). The trial evaluated pumitamig in combination with chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC). The data, consistent with a prior Phase 2 trial in China, ...